{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:03:36Z","timestamp":1762506216301},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/cco.0000000000000030","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T15:58:52Z","timestamp":1386086332000},"page":"51-61","source":"Crossref","is-referenced-by-count":17,"title":["Inherited cancer syndromes and the thyroid"],"prefix":"10.1097","volume":"26","author":[{"given":"Rosemarie","family":"Metzger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Milas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/GIM.0b013e318216cc6d","article-title":"Multiple endocrine neoplasia type 2: an overview.","volume":"13","author":"Moline","year":"2011","journal-title":"Genet Med"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.14310\/horm.2002.1111011","article-title":"A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A.","volume":"6","author":"Bethanis","year":"2007","journal-title":"Hormones (Athens)"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1210\/jc.2003-030997","article-title":"A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.","volume":"88","author":"Da Silva","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2265.2006.02509.x","article-title":"A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening.","volume":"64","author":"Kaldrymides","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1530\/EJE-08-0476","article-title":"Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.","volume":"159","author":"Peppa","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association.","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00268-006-0769-y","article-title":"Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.","volume":"31","author":"Machens","year":"2007","journal-title":"World J Surg"},{"issue":"Suppl 1","key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.6061\/clinics\/2012(Sup01)19","article-title":"Multiple endocrine neoplasia type 2: achievements and current challenges.","volume":"67","author":"Machens","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-12-0919","article-title":"Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium.","volume":"168","author":"Machens","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/1756-6614-6-S1-S12","article-title":"Results and summary of voting among the audience during presentation and discussion of medullary thyroid carcinoma clinical guidelines prepared by American Thyroid Association.","volume":"6","author":"Feldt-Rasmussen","year":"2013","journal-title":"Thyroid Res"},{"issue":"Suppl 1","key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1756-6614-6-S1-S9","article-title":"Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers: the role of Ct serum level.","volume":"6","author":"Jarzab","year":"2013","journal-title":"Thyroid Res"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/jc.2011-2046","article-title":"The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.","volume":"97","author":"Elisei","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/cncr.26283","article-title":"Medullary thyroid microcarcinoma: a population-level analysis of 310 patients.","volume":"118","author":"Kazaure","year":"2012","journal-title":"Cancer"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1210\/jc.2011-2534","article-title":"Biological relevance of medullary thyroid microcarcinoma.","volume":"97","author":"Machens","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/SLA.0b013e3181ae333f","article-title":"Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.","volume":"250","author":"Machens","year":"2009","journal-title":"Ann Surg"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1210\/jc.2013-1115","article-title":"Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.","volume":"98","author":"Massicotte","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"K51","DOI":"10.1530\/EJE-13-0015","article-title":"Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.","volume":"168","author":"Scheffel","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12022-012-9225-8","article-title":"Prognostic and predictive markers in medullary thyroid carcinoma.","volume":"23","author":"Erovic","year":"2012","journal-title":"Endocr Pathol"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"803171","DOI":"10.1155\/2013\/803171","article-title":"Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.","volume":"2013","author":"Giunti","year":"2013","journal-title":"Int J Endocrinol"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2011.04296.x","article-title":"Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.","volume":"77","author":"Druce","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1582-4934.2011.01438.x","article-title":"Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.","volume":"16","author":"Faggiano","year":"2012","journal-title":"J Cell Mol Med"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jmedgenet-2012-101412","article-title":"Risk of thyroid cancer in first-degree relatives of patients with nonmedullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries.","volume":"50","author":"Fallah","year":"2013","journal-title":"J Med Genet"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1089\/thy.2013.0079","article-title":"Familial nonmedullary thyroid carcinoma.","volume":"23","author":"Mazeh","year":"2013","journal-title":"Thyroid"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s00268-006-0847-1","article-title":"An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.","volume":"31","author":"Sippel","year":"2007","journal-title":"World J Surg"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1089\/thy.2011.0349","article-title":"Ultrasonographic screening for thyroid cancer in siblings of patients with apparently sporadic papillary carcinoma.","volume":"22","author":"Rosario","year":"2012","journal-title":"Thyroid"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/thy.2011.0192","article-title":"In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.","volume":"22","author":"Mazeh","year":"2012","journal-title":"Thyroid"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"E973","DOI":"10.1210\/jc.2012-3823","article-title":"SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.","volume":"98","author":"He","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"e61920","DOI":"10.1371\/journal.pone.0061920","article-title":"Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance.","volume":"8","author":"He","year":"2013","journal-title":"PLoS One"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1158\/0008-5472.CAN-08-1071","article-title":"A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24.","volume":"69","author":"He","year":"2009","journal-title":"Cancer Res"},{"key":"R37-9-20210128","first-page":"1201","article-title":"Should patients with Cowden syndrome undergo prophylactic thyroidectomy S","volume":"152","author":"Milas","year":"2012","journal-title":"urgery"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"E2063","DOI":"10.1210\/jc.2011-1616","article-title":"Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.","volume":"96","author":"Ngeow","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jmedgenet-2012-101339","article-title":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.","volume":"50","author":"Bubien","year":"2013","journal-title":"J Med Genet"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations.","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajhg.2010.11.013","article-title":"A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.","volume":"88","author":"Tan","year":"2011","journal-title":"Am J Hum Genet"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/SLA.0b013e3181fcba8a","article-title":"Screening for thyroid cancer in patients with familial adenomatous polyposis.","volume":"253","author":"Jarrar","year":"2011","journal-title":"Ann Surg"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.clcc.2012.01.006","article-title":"The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized.","volume":"11","author":"Steinhagen","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cgh.2006.10.019","article-title":"Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations.","volume":"5","author":"Herraiz","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00268-004-7475-4","article-title":"Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer.","volume":"28","author":"Tomoda","year":"2004","journal-title":"World J Surg"},{"key":"R47-9-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1507\/endocrj.EJ11-0022","article-title":"Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients.","volume":"58","author":"Ito","year":"2011","journal-title":"Endocr J"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:09Z","timestamp":1620950109000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201401000-00009"}},"subtitle":["an update"],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000030","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}